NABNEC: A Randomised Phase II Study Of Nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

晚期神经内分泌癌(NEC)患者的癌症预后是最差的之一。到目前为止，还没有进行随机试验来确认NEC的治疗。根据肺癌试验，目前的NEC化疗是依托泊苷和卡铂(EC)。NABNEC的研究将与卡铂或EC一起使用新药NAB-紫杉醇，收集PET扫描、肿瘤和血液样本结果，以帮助了解治疗效果，并最终改善NEC患者的健康并推进未来的研究。

Patients with advanced neuroendocrine carcinomas (NEC) have one of the poorest cancer outcomes. So far, no randomised trials have been done to confirm NEC treatment. Current NEC chemotherapy is etoposide & carboplatin (EC), based on lung cancer trials. The NABNEC study will use a new drug, nab-paclitaxel, with carboplatin or EC, collect PET scan, tumour & blood samples result to help understand how treatment works and to ultimately improve NEC patients’ health and progress future research.